Imatinib Tad (Imatinib)

Imatinib blocks the ATP‑binding pockets of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By inhibiting these enzymes, it stops downstream signaling that promotes cell proliferation and survival, leading to apoptosis of cancer cells that rely on these pathways.

The exact dose of Imatinib Tad is determined by the prescribing physician based on the patient’s diagnosis, disease stage, body weight, renal and hepatic function, and other clinical factors. Dosing regimens are individualized and should follow the prescriber’s written instructions.

The safety of Imatinib Tad in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception and pregnancy planning with their healthcare provider.

To request Imatinib Tad, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib Tad belongs to the class of tyrosine‑kinase inhibitors and is considered a first‑line targeted therapy for CML, Philadelphia‑positive ALL and GIST. Compared with conventional chemotherapy, it offers a more specific mechanism of action, often resulting in higher response rates and a different side‑effect profile. Alternative TKIs exist, but choice depends on disease characteristics, resistance patterns and physician judgment.

Imatinib Tad should be stored at temperatures below 25 °C in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat. Do not store in the bathroom or near kitchen appliances that generate heat.

Imatinib Tad is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals.

Serious risks include severe neutropenia, hepatotoxicity, cardiac dysfunction (including reduced left‑ventricular ejection fraction), pulmonary hypertension, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for these events, and any concerning symptoms should prompt immediate medical evaluation.

Imatinib Tad is contraindicated in patients with known hypersensitivity to imatinib or any of its excipients. It should be used with caution in individuals with pre‑existing severe liver disease, cardiac failure, or uncontrolled infections. Pregnant or breastfeeding women should only use it when the potential benefits outweigh the risks.